Pfizer Inc.'s $5.2 billion acquisition of Anacor Pharmaceuticals Inc. to collect crisaborole sweeps one soldier off the atopic dermatitis (eczema) field, but plenty remain – with varying approaches and hard-to-handicap odds in what ISI Evercore analyst Mark Schoenebaum called a "not very developed" but potentially lucrative market.